Learn More About the PACIFICA Trial

The PACIFICA trial is a randomized study in several categories of myelofibrosis, an uncommon type of cancer that affects the body’s blood and bone health. The purpose of this site is to educate health care professionals about the ongoing research in this area and opportunities for patient enrollment.

To learn more about this trial, visit:

ClinicalTrials.gov

Consult your doctor or other qualified healthcare provider with any questions you may have regarding your medical condition, or treatments.

PACIFICA Trial Site Locations

Enrollment is ongoing / proposed in the countries below. For a full list of PACIFICA clinical sites and site enrollment status, visit ClinicalTrials.gov.

World Map
  • United States*
  • Australia
  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Georgia
  • India
  • Israel
  • Italy
  • Japan
  • Kazakhstan
  • Korea, Republic of
  • Poland
  • Romania
  • Russian Federation**
  • Serbia
  • Spain
  • Ukraine**
    • >
  • United Kingdom

*Pacritinib (commercially known as VONJO™) was approved by U.S. Food and Drug Administration (FDA) on February 28, 2022 for the treatment of adults with myelofibrosis with a platelet count below 50 x 109/L.

As the approved indication is identical to the patients enrolling on PACIFICA, enrollment of additional patients in the U.S. was closed effective March 2022.

**Enrollment is closed in Russian Federation and Ukraine.




Contact Us
cti biopharma

You are now leaving this page

OK Cancel